NZ595829A - 8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f]-1,6-naphthyridine derivatives - Google Patents

8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f]-1,6-naphthyridine derivatives

Info

Publication number
NZ595829A
NZ595829A NZ595829A NZ59582907A NZ595829A NZ 595829 A NZ595829 A NZ 595829A NZ 595829 A NZ595829 A NZ 595829A NZ 59582907 A NZ59582907 A NZ 59582907A NZ 595829 A NZ595829 A NZ 595829A
Authority
NZ
New Zealand
Prior art keywords
phenyl
triazolo
naphthyridin
cyclobutanamine
aminocyclobutyl
Prior art date
Application number
NZ595829A
Inventor
Michael Kelly
Mark E Layton
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of NZ595829A publication Critical patent/NZ595829A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)

Abstract

595829 Disclosed are 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f]-1,6-naphthyridine derivatives as represented by the general formula C, wherein ring Y is (C4-C7)cycloalkyl group, and wherein the other substituents are as defined herein, with the proviso that 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f]-1,6-naphthyridin-3 (2H)-one and its pharmaceutically acceptable salts are excluded. Representative compounds include 1-{ 4-[3-(1-methyl-1H-imidazol-4-yl)-9-phenyl[1,2,4]triazolo[3,4-f]-1,6-naphthyridin-8-yl]phenyl} cyclobutanamine dihydrochloride, tert-butyl { 1-[4-(9-phenyl(1,2,4]triazolo[3,4-f]-1,6-naphthyridin-8-yl)phenyl]cyclobutyl} carbamate, 1-[4-(9-phenyl-3-pyrimidin-2-yl[1,2,4 ]triazolo[3,4-f]-1,6-naphthyridin-8-yl)phenyl]cyclobutanamine, 1-[4-(3-methyl-9-phenyl[1,2,4]triazolo[3,4-f]-1,6-naphthyridin-5-yl)phenyl]cyclobutanamine and 1-[4-(3-cyclopropyl-9-phenyl[1,2,4]triazolo[3,4-f]-1,6-naphthyridin-5-yl)phenyl]cyclobutanamine. Also disclosed is a pharmaceutical composition which comprises a pharmaceutical carrier, and a therapeutically effective amount of a compound as defined above, useful in the treatment or prevention of cancer.
NZ595829A 2006-12-06 2007-12-03 8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f]-1,6-naphthyridine derivatives NZ595829A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US87319806P 2006-12-06 2006-12-06
US88066107P 2007-01-16 2007-01-16
US96787207P 2007-09-06 2007-09-06
NZ577470A NZ577470A (en) 2006-12-06 2007-12-03 Substituted naphthyridine compounds as inhibitors of akt activity

Publications (1)

Publication Number Publication Date
NZ595829A true NZ595829A (en) 2013-04-26

Family

ID=39492823

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ577470A NZ577470A (en) 2006-12-06 2007-12-03 Substituted naphthyridine compounds as inhibitors of akt activity
NZ595829A NZ595829A (en) 2006-12-06 2007-12-03 8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f]-1,6-naphthyridine derivatives

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ577470A NZ577470A (en) 2006-12-06 2007-12-03 Substituted naphthyridine compounds as inhibitors of akt activity

Country Status (30)

Country Link
US (3) US7576209B2 (en)
EP (1) EP2104669B1 (en)
JP (2) JP4431636B1 (en)
KR (1) KR101110598B1 (en)
CN (1) CN101600706B (en)
AR (1) AR064010A1 (en)
AU (1) AU2007328286B2 (en)
BR (1) BRPI0719580A2 (en)
CA (1) CA2670760C (en)
CL (1) CL2007003495A1 (en)
CO (1) CO6190528A2 (en)
CR (1) CR10851A (en)
EA (1) EA016195B1 (en)
EC (1) ECSP099376A (en)
ES (1) ES2527567T3 (en)
GE (1) GEP20125469B (en)
GT (1) GT200900146A (en)
HK (1) HK1137758A1 (en)
HN (1) HN2009001112A (en)
IL (2) IL198826A (en)
MA (1) MA31027B1 (en)
MX (1) MX2009006052A (en)
NI (1) NI200900106A (en)
NO (1) NO20092569L (en)
NZ (2) NZ577470A (en)
PE (1) PE20081341A1 (en)
SV (1) SV2009003283A (en)
TN (1) TN2009000224A1 (en)
TW (1) TWI386410B (en)
WO (2) WO2008070041A2 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ563423A (en) * 2005-06-10 2010-05-28 Merck Sharp & Dohme Inhibitors of AKT activity
AR064010A1 (en) * 2006-12-06 2009-03-04 Merck & Co Inc AKT ACTIVITY INHIBITORS
WO2008070134A1 (en) * 2006-12-06 2008-06-12 Merck & Co., Inc. Inhibitors of akt activity
US20100048912A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
JP2011522048A (en) * 2008-06-03 2011-07-28 メルク・シャープ・エンド・ドーム・コーポレイション Inhibitor of AKT activity
EP2299825B1 (en) * 2008-06-03 2013-07-31 Merck Sharp & Dohme Corp. Inhibitors of akt activity
EP2307422B1 (en) 2008-07-04 2014-03-26 Msd K.K. Novel spirochromanone carboxylic acids
BRPI0917936A2 (en) 2008-08-25 2017-07-11 Irm Llc HEDGEHOG TRACK MODULATORS
DE102008043724A1 (en) * 2008-11-13 2010-05-20 Biotronik Vi Patent Ag Increasing the efficiency of pharmaceutical active ingredient-releasing medical devices by combination with an inhibitor of the transport protein P-glycoprotein
US20110288090A1 (en) * 2009-02-02 2011-11-24 Armstrong Donna J Inhibitors of AKT Activity
ES2552087T3 (en) 2009-02-05 2015-11-25 Tokai Pharmaceuticals, Inc. New prodrugs of steroid / antiandrogen CYP17 inhibitors
EP2403339B1 (en) * 2009-03-06 2017-01-18 Merck Sharp & Dohme Corp. Combination cancer therapy with an akt inhibitor and other anticancer agents
EP2405756B1 (en) 2009-03-12 2013-07-03 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
JP5567136B2 (en) 2009-09-08 2014-08-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 4-Substituted pyridin-3-yl-carboxamide compounds and methods of use
US8546376B2 (en) 2009-09-18 2013-10-01 Almac Discovery Limited Pharmaceutical compounds
GB0919380D0 (en) 2009-11-04 2009-12-23 Almac Discovery Ltd Pharmaceutical compouds
GB0922589D0 (en) 2009-12-23 2010-02-10 Almac Discovery Ltd Pharmaceutical compounds
WO2011130921A1 (en) * 2010-04-23 2011-10-27 Merck Sharp & Dohme Corp. Inhibitors of akt activity
JP2013526578A (en) 2010-05-21 2013-06-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー combination
US8975265B2 (en) 2010-07-12 2015-03-10 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-a]pyrimidines and —pyridines
US20130184273A1 (en) 2010-07-13 2013-07-18 Bayer Intellectual Property Gmbh Bicyclic pyrimidines
EP2598505B1 (en) 2010-07-28 2015-03-18 Bayer Intellectual Property GmbH Substituted imidazo[1,2-b]pyridazines
US8987286B2 (en) * 2010-12-16 2015-03-24 Bayer Intellectual Property Gmbh Substituted pyrimido[1,2-b]indazoles and their use as modulators of the Pi3K/Akt pathway
EP2663189B1 (en) * 2011-01-11 2018-07-04 Novartis AG Combination of bortezomib with afuresertib and use thereof in the treatment of cancer
EP2698372B1 (en) 2011-04-06 2016-02-03 Taiho Pharmaceutical Co., Ltd. Novel imidazo-oxazine compound or salt thereof
MA35016B1 (en) * 2011-04-07 2014-04-03 Bayer Ip Gmbh IMIDAZOPYRIDAZINES AS KINASE AKT INHIBITORS
US8815854B2 (en) 2011-06-24 2014-08-26 Arqule, Inc. Substituted imidazopyridinyl compounds
MX339862B (en) * 2011-06-24 2016-06-15 Arqule Inc Substituted imidazopyridinyl-aminopyridine compounds.
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
WO2013104610A1 (en) 2012-01-10 2013-07-18 Bayer Intellectual Property Gmbh Substituted imidazopyrazines as akt kinase inhibitors
US9370517B2 (en) 2012-01-10 2016-06-21 Bayer Intellectual Property Gmbh Substituted pyrazolopyrimidines as Akt kinase inhibitors
AU2013209580B2 (en) 2012-01-20 2017-11-30 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Enhanced glycemic control using Ad36E4orf1 and AKT1 inhibitor
GB201205164D0 (en) 2012-03-23 2012-05-09 Almac Discovery Ltd Pharmaceutical compounds
RU2618423C2 (en) 2012-07-02 2017-05-03 Тайхо Фармасьютикал Ко., Лтд. Antitumor effect amplifyer containing imidazooxaazine compound
MX2015012274A (en) 2013-03-14 2016-06-02 Univ Maryland Androgen receptor down-regulating agents and uses thereof.
CN105764502A (en) 2013-07-26 2016-07-13 现代化制药公司 Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
KR20160058774A (en) 2013-08-12 2016-05-25 토카이 파마슈티컬, 아이엔씨. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
MX2016004265A (en) 2013-10-01 2016-07-08 Novartis Ag Enzalutamide in combination with afuresertib for the treatment of cancer.
AU2014330779A1 (en) 2013-10-01 2016-04-07 Novartis Ag Combination
WO2015094928A1 (en) * 2013-12-17 2015-06-25 Merck Sharp & Dohme Corp. Liposomal compositions for allosteric akt inhibitors
SG11201606239UA (en) 2014-01-28 2016-08-30 Buck Inst For Res On Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
JP2017507963A (en) 2014-03-12 2017-03-23 ノバルティス アーゲー A combination comprising a BTK inhibitor and an AKT inhibitor
ES2872552T3 (en) * 2014-03-17 2021-11-02 Merck Sharp & Dohme Polymeric nanoparticles and methods of their preparation and use
EP3263573B1 (en) 2015-02-27 2019-12-04 Taiho Pharmaceutical Co., Ltd. Crystal of imidazo-oxazine, pharmaceutical composition containing said crystal, and method for producing said crystal
FR3033499A1 (en) * 2015-03-11 2016-09-16 Centre Leon-Berard COMPOSITION FOR THE TREATMENT OF PANCREATIC NEUROENDOCRINE TUMORS
JP6853782B2 (en) * 2015-10-22 2021-03-31 田辺三菱製薬株式会社 New bicyclic heterocyclic compound
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
CN108426971B (en) * 2018-03-09 2020-03-20 浙江中一检测研究院股份有限公司 Method for rapidly detecting microcystin in water
WO2019221755A1 (en) 2018-05-18 2019-11-21 Bioventures, Llc Piperlongumine analogues and uses thereof
MX2022014019A (en) * 2020-05-08 2023-02-16 Georgiamune Llc Akt3 modulators and methods of use thereof.
WO2024083716A1 (en) 2022-10-17 2024-04-25 Astrazeneca Ab Combinations of a serd for the treatment of cancer

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002252614B2 (en) 2001-04-10 2006-09-14 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
JP2004527531A (en) * 2001-04-10 2004-09-09 メルク　エンド　カムパニー　インコーポレーテッド How to treat cancer
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US7273869B2 (en) 2002-04-08 2007-09-25 Merck & Co., Inc. Inhibitors of Akt activity
WO2003086394A1 (en) 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
AU2003226250B2 (en) 2002-04-08 2007-08-16 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
WO2003086403A1 (en) 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
ATE503483T1 (en) 2002-10-30 2011-04-15 Merck Sharp & Dohme ACT ACTIVITY INHIBITOR
ATE461179T1 (en) 2003-04-24 2010-04-15 Merck Sharp & Dohme ACT ACTIVITY INHIBITOR
AU2004233835B2 (en) 2003-04-24 2010-02-25 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
JP2006524254A (en) * 2003-04-24 2006-10-26 メルク　エンド　カムパニー　インコーポレーテッド Inhibitor of AKT activity
WO2004096131A2 (en) 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibitors of akt activity
WO2005007099A2 (en) 2003-07-10 2005-01-27 Imclone Systems Incorporated Pkb inhibitors as anti-tumor agents
JP2007008816A (en) * 2003-10-15 2007-01-18 Ube Ind Ltd New isoquinoline derivative
ES2426288T3 (en) * 2003-10-15 2013-10-22 Ube Industries, Ltd. Novel imidazole derivative
EP1737843B1 (en) 2004-04-09 2011-02-23 Merck Sharp & Dohme Corp. Inhibitors of akt activity
EP1737861A4 (en) 2004-04-09 2010-04-28 Merck Sharp & Dohme Inhibitors of akt activity
US7544677B2 (en) 2004-08-23 2009-06-09 Merck & Co., Inc. Inhibitors of Akt activity
US20080015212A1 (en) 2004-12-02 2008-01-17 Barnett Stanley F Inhibitors Of Akt Activity
EP1827436A4 (en) 2004-12-15 2011-08-10 Merck Sharp & Dohme Inhibitors of akt activity
JP2008530111A (en) 2005-02-14 2008-08-07 メルク エンド カムパニー インコーポレーテッド Inhibitor of Akt activity
WO2006110638A2 (en) * 2005-04-12 2006-10-19 Merck & Co., Inc. Inhibitors of akt activity
NZ563423A (en) 2005-06-10 2010-05-28 Merck Sharp & Dohme Inhibitors of AKT activity
EP1978966A4 (en) * 2006-01-23 2010-11-10 Amira Pharmaceuticals Inc Tricyclic inhibitors of 5-lipoxygenase
AR064010A1 (en) * 2006-12-06 2009-03-04 Merck & Co Inc AKT ACTIVITY INHIBITORS
JP5516397B2 (en) * 2007-04-05 2014-06-11 アムジエン・インコーポレーテツド Aurora kinase modulator and method of use

Also Published As

Publication number Publication date
BRPI0719580A2 (en) 2013-12-17
WO2008070041A2 (en) 2008-06-12
US7576209B2 (en) 2009-08-18
CA2670760A1 (en) 2008-06-12
TN2009000224A1 (en) 2010-10-18
PE20081341A1 (en) 2008-10-19
EP2104669A2 (en) 2009-09-30
CN101600706A (en) 2009-12-09
KR101110598B1 (en) 2012-03-08
US20110160183A1 (en) 2011-06-30
AR064010A1 (en) 2009-03-04
CO6190528A2 (en) 2010-08-19
WO2008070016A2 (en) 2008-06-12
JP2010511703A (en) 2010-04-15
EP2104669B1 (en) 2014-10-15
GT200900146A (en) 2010-04-13
JP4431636B1 (en) 2010-03-17
JP2009298786A (en) 2009-12-24
CN101600706B (en) 2013-10-16
CL2007003495A1 (en) 2008-05-30
NO20092569L (en) 2009-07-06
HN2009001112A (en) 2011-07-22
WO2008070016A3 (en) 2008-09-12
EA016195B1 (en) 2012-03-30
ES2527567T3 (en) 2015-01-26
CR10851A (en) 2009-06-25
ECSP099376A (en) 2009-07-31
GEP20125469B (en) 2012-04-10
US20090253734A1 (en) 2009-10-08
TW200831509A (en) 2008-08-01
US8288407B2 (en) 2012-10-16
TWI386410B (en) 2013-02-21
SV2009003283A (en) 2009-11-09
MX2009006052A (en) 2009-06-17
IL205220A0 (en) 2011-07-31
HK1137758A1 (en) 2010-08-06
MA31027B1 (en) 2009-12-01
JP5364454B2 (en) 2013-12-11
US20080161317A1 (en) 2008-07-03
AU2007328286A1 (en) 2008-06-12
CA2670760C (en) 2012-01-24
AU2007328286B2 (en) 2011-01-20
KR20090086095A (en) 2009-08-10
EA200970542A1 (en) 2009-12-30
NZ577470A (en) 2011-11-25
IL198826A (en) 2010-11-30
AU2007328286A2 (en) 2009-08-06
WO2008070041A3 (en) 2008-08-28
NI200900106A (en) 2010-01-20

Similar Documents

Publication Publication Date Title
NZ595829A (en) 8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f]-1,6-naphthyridine derivatives
EP2288260A4 (en) Triazolopyridine jak inhibitor compounds and methods
MX336271B (en) Triazolopyridine jak inhibitor compounds and methods.
MY142768A (en) Gfat inhibitors
NO20064400L (en) Proline derivatives, and use of the same as inhibitors of dipeptidyl peptidase IV
TW200621762A (en) Novel compounds
PE20090887A1 (en) DERIVATIVES OF 1H-PYRAZOLE- [3,4-d] -PYRIMIDINE, 9H-PURINE AND 7H-PYRROL- [2,3-d] -PYRIMIDINE AS KINASE INHIBITORS P70 S6
TW200745032A (en) Novel heterobicyclic derivatives
TW200615266A (en) Organic compounds
NZ590355A (en) Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
MXPA06009475A (en) Quinazoline derivatives and therapeutic use thereof.
JP2005510473A5 (en)
GEP20105126B (en) Fused pyrazole derivatives and uses thereof in methods of treatment of metabolic-related disorders
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
IN2012DN00755A (en)
ATE370138T1 (en) NEW IMIDAZOPYRIDINES AND THEIR USE
HRP20120738T1 (en) Akt and p70 s6 kinase inhibitors
TW200626598A (en) Pyrrazolo-pyrimidine derivatives
TW200738698A (en) Organic compounds
TNSN07361A1 (en) 3,4-substituted pyrrolidine derivatives for the treatment of hypertension
NO20064010L (en) Indazole derivatives and pharmaceutical preparations contain such
WO2007084560A3 (en) INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH
MX2010009922A (en) Pyridazinone glucokinase activators.
WO2007084914A3 (en) Phenoxy-substituted pyrimidines as adenosine receptor antagonists
WO2008104175A3 (en) Novel phosphodiesterase inhibitors

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: SCHERING CORPORATION, US

Free format text: OLD OWNER(S): MERCK SHARP AND DOHME CORP.

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 03 DEC 2014 BY AJ PARK

Effective date: 20131031

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 03 DEC 2017 BY THOMSON REUTERS

Effective date: 20140912

LAPS Patent lapsed